Sahajanand Medical Technologies shares to list today: Check GMP ahead of debut - The
The Rs 475.48 crore IPO comprised an offer for sale (OFS) of 1.38 crore shares. Since the issue was entirely an OFS, the company will not receive any proceeds from the offering. Instead, the proceeds will go to the existing shareholders selling their stakes.
Shares of Sahajanand Medical Technologies are set to make their debut on the BSE and NSE on Friday, with grey market trends pointing to a potentially modest listing gain. The IPO is commanding a grey market premium (GMP) of around 5%, indicating positive but measured expectations ahead of its stock market debut.The Rs 475.48 crore IPO comprised an offer for sale (OFS) of 1.38 crore shares. Since the issue was entirely an OFS, the company will not receive any proceeds from the offering.
Instead, the proceeds will go to the existing shareholders selling their stakes.The IPO, which opened for subscription on October 15, 2026, and closed on October 19, received an overall subscription of 14.21 times. The retail investor portion was subscribed 3.04 times, while the non-institutional investor (NII) segment saw 14.64 times subscription. The qualified institutional buyer (QIB) portion was subscribed 34.70 times.Sahajanand Medical Technologies had fixed the IPO price band at Rs 327–Rs 344 per share.The IPO lot size was 43 shares, translating into a minimum investment of Rs 14,792 for retail investors applying at the upper end of the price band.Ahead of the public issue, Sahajanand Medical Technologies raised Rs 140 crore from anchor investors by allotting 40,71,634 equity shares at Rs 344 apiece, the upper end of the price band.Motilal Oswal Investment Advisors, Avendus Capital, HSBC Securities & Capital Markets (India) and Nuvama Wealth Management are the book-running lead managers for the issue, while MUFG Intime India has been appointed as the registrar.Sahajanand Medical Technologies IPO GMP TodaySahajanand Medical Technologies’ latest grey market premium (GMP) stood at Rs 16 per share, implying a premium of around 5% over the IPO’s upper price band of Rs 344.
At this premium, the estimated listing price works out to Rs 360 per share. However, the GMP is an unofficial indicator of market sentiment and does not guarantee the actual listing price or returns. It may fluctuate before the shares make their stock market debut.Financial PerformanceSahajanand Medical Technologies Ltd.’s total income increased 18% to Rs 1,219 crore in FY26 from Rs 1,036 crore in FY25.
Profit after tax (PAT) surged 175% to Rs 69 crore in FY26, compared with Rs 25 crore in the previous financial year.About Sahajanand Medical TechnologiesIncorporated in October 2001, Sahajanand Medical Technologies Ltd. is a medical technology company engaged in developing, manufacturing and marketing advanced medical devices, primarily for vascular and structural heart interventions. Its product portfolio includes coronary stents, balloons, transcatheter aortic valve implantation (TAVI) devices, occluders, renal stents and peripheral drug-coated balloons.
Its flagship brands include Supraflex Cruz, Cocoon and Hydra, supported by a focus on research, precision manufacturing and product innovation.The company operates three manufacturing facilities across India and Thailand, along with two research and development centres. As of June 30, 2026, it held 119 patents globally, with 78 patent applications in the pipeline, and marketed its products in 77 countries in FY26.
Revenue from operations rose to Rs 1,210.50 crore in FY26 from Rs 1,024.88 crore in FY25 and Rs 901.60 crore in FY24. As of June 30, 2026, the company had 1,605 full-time employees, 31 consultants and 707 contract workers.Disclaimer: The views/recommendations mentioned in this article, wherever applicable, are those of the respective SEBI-registered Research Analyst/brokerage and have been reproduced/reported with due attribution.
They should not be construed as the views or recommendations of The Economic Times Digital or the journalist. Readers are advised to consider the original research report and make their investment decisions based on their own assessment. Brokerage disclaimers here
